Tech Company Financing Transactions
Cullinan Oncology Funding Round
F2 Ventures and MPM Capital participated in a $98.5 million Series B capital raise for Cullinan Oncology. The round was announced on 6/5/2020.
Transaction Overview
Company Name
Announced On
6/5/2020
Transaction Type
Venture Equity
Amount
$98,500,000
Round
Series B
Investors
MPM Capital (Jon Wigginton)
Proceeds Purpose
This capital infusion positions us well to execute our vision of bringing a diversified portfolio of innovative oncology assets into the clinic.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Main St. 520
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Cullinan (Nasdaq: CGEM) was formed to capitalize on the latest scientific breakthroughs by advancing a dynamic portfolio of innovative, early-stage assets. We develop both internally generated and externally sourced cancer therapeutics through a novel, cost efficient business model.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Owen Hughes
Chief Medical Officer
Jon Wigginton
Chief Scientific Officer
Patrick Baeuerle
Chief Scientific Officer
Leigh Zawel
VP - Bus. Development
Jennifer Michaelson
VP - Bus. Development
Asher Page
VP - Bus. Development
Corinne Savill
VP - General Counsel
Gregory Sieczkiewicz
VP - Operations
Myles Clancy
VP - R & D
David Witter
Browse more venture capital transactions:
Prev: 6/5/2020: Magic Identity venture capital transaction
Next: 6/5/2020: Greeneye Technology venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs